Streetbeat News

Price Targets

CRWD

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on CrowdStrike Holdings (NASDAQ:CRWD) and raises the price target from $170 to $180.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 1:32 pm

META

MSFT

NVDA

SPY

TSLA

Market Clubhouse Morning Memo focuses on SPY, NVDA, TSLA, MSFT, and META, providing price levels based on a proprietary formula. The analysis includes potential breakouts or reversals for each stock, with upside and downside targets.

Portfolio Pulse from RIPS

May 30, 2023 | 1:28 pm

CRSP

William Blair analyst Sami Corwin reinstates CRISPR Therapeutics (NASDAQ:CRSP) with an Outperform rating and announces a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

May 30, 2023 | 1:25 pm

FSM

Scotiabank analyst Eric Winmill reinstated Fortuna Silver Mines (NYSE:FSM) with a Sector Perform rating and announced a $4.25 price target.

Portfolio Pulse from richadhand@benzinga.com

May 30, 2023 | 1:24 pm

SLRN

Jefferies analyst Akash Tewari initiates coverage on Acelyrin (NASDAQ:SLRN) with a Buy rating and announces a price target of $31.

Portfolio Pulse from richadhand@benzinga.com

May 30, 2023 | 1:24 pm

TYGO

Northland Capital Markets analyst Gus Richard initiates coverage on Tigo Energy (NASDAQ:TYGO) with an Outperform rating and a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

May 30, 2023 | 1:23 pm

KVUE

UBS analyst Peter Grom initiates coverage on Kenvue (NYSE:KVUE) with a Neutral rating and announces a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

May 30, 2023 | 1:23 pm

HGBL

Craig-Hallum analyst George Sutton initiates coverage on Heritage Glb (NASDAQ:HGBL) with a Buy rating and announces a price target of $6.

Portfolio Pulse from richadhand@benzinga.com

May 30, 2023 | 1:22 pm

CKPT

Lake Street analyst Thomas Flaten maintains a Buy rating on Checkpoint Therapeutics (NASDAQ:CKPT) but lowers the price target from $22 to $16.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 1:12 pm

ICPT

B. Riley Securities analyst Mayank Mamtani maintains a Buy rating on Intercept Pharma (NASDAQ:ICPT) but lowers the price target from $30 to $15.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2023 | 1:10 pm